Results 131 to 140 of about 29,631 (205)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

open access: yes, 2022
Along with their level of protection against COVID-19, SARS-CoV-2-specific antibodies decline over time following vaccination with BNT162b2. However, relevant data on AZD1222 are scarce.
Maria Gavriatopoulou   +10 more
core   +1 more source

Acute interstitial nephritis after vaccination with BNT162b2 [PDF]

open access: yesJournal of Nephrology, 2022
Rieckmann, Sonja   +7 more
openaire   +2 more sources

Effectiveness of BNT162b2 against COVID-19 in adolescents

open access: yesThe Lancet Infectious Diseases, 2022
Powell, Annabel A   +8 more
openaire   +2 more sources

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients

open access: yes
In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown.
Arosemena, Leopoldo   +14 more
core   +1 more source

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar

open access: yesNew England Journal of Medicine, 2022
Laith J. Abu-Raddad   +2 more
openaire   +2 more sources

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting

open access: yesScientific Reports
This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID 
Aini Syahida Mat Yassim   +11 more
doaj   +1 more source

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study

open access: yes
Background: The evidence of SARS-CoV-2 vaccine effectiveness in people living with HIV (PLWH) is limited. This study evaluated the humoral immune response to CoronaVac™ (virus inactivated) and BNT162b2 (mRNA- based) vaccines in PLWH and HIV-negative ...
Vial Cox, María Cecilia   +6 more
core   +1 more source

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination

open access: yesDrug Design, Development and Therapy
Leonidas D Panos,1,2 Panagiotis Bargiotas,2 Georgios Hadjigeorgiou,2 Georgios D Panos3,4 1Department of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland; 2Department of Neurology, School of Medicine, University of Cyprus, Nicosia ...
Panos LD   +3 more
doaj  

Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil

open access: yesBMJ Public Health
Objectives To compare antispike IgG levels over a period of 182 days of follow-up in healthy adults who received full or fractional booster doses of BNT162b2 or AZD1222 after completing a primary series of Sinovac, BNT162b2 or AZD1222.Design Double-blind,
Haley Hedlin   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy